Precedence Research recently published a report on “Plasmid DNA Manufacturing Market (By Product: Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others; By Application: Gene Therapy, DNA Vaccines, Immunotherapy, Others; By Disease: Infectious Disease, Genetic Disorder, and Cancer) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030”, The global plasmid DNA manufacturing market size is projected to reach USD 2.1 billion by 2030 from an estimated USD 306.4 million in 2020, at a CAGR of 21.7% from 2021 – 2030.
The market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents breakdown of market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift at global, regional, and country from 2017 to 2030. This research report evaluates plasmid DNA manufacturing market on a global and regional level. It offers thorough analysis of market status, growth and forecast of the global plasmid DNA manufacturing market for the period from 2017 to 2030.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1299
Crucial factors accountable for market growth are:
Scope of the Plasmid DNA Manufacturing Market
| Report Coverage | Details |
| Market Size in 2020 | USD 306.4 Million |
| Growth Rate from 2021 to 2030 | CAGR of 21.7% |
| Base Year | 2021 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product Type, Application Type, Disease Type, Regional Outlook |
Report Highlights
Scope of the Study
This plasmid DNA manufacturing market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes market by players, type, application, and region. This report also studies global market prominence, competitive landscape, market share, growth rate market dynamics such as drivers, restraints and opportunities, and distributors and sales channel.
This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers competitive scenario which comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.
Market Dynamics
Drivers
The growing usage of plasmid DNA for the development of vaccines is fueling the demand. The plasmid DNA is extensively used for developing vaccines for diseases such as influenza, HIV, malaria, pathogens, and Ebola. The DNA vaccines are highly effective and hence, it is increasingly used, thereby fostering the consumption of plasmid DNA.
Restraints
Various risks related to gene therapies like mutagenesis may hamper the market growth. Further, stringent government regulations and high costs involved may restrict the adoption of gene therapies. These factors have an adverse effect on the market.
Opportunities
Growing investments and innovations in the biopharmaceutical industry to develop innovative manufacturing technologies to increase the commercial production output of the plasmid DNA may have a big impact on the market during the forecast period.
Challenges
Lack of adequate infrastructure and financial limitations poses a challenge to carry on the smooth functioning of the research and developmental activities in the field of plasmid DNA manufacturing.
Regional Snapshots
North America is the leading plasmid DNA manufacturing market. The growing investments in the development of new biopharmaceutical medicines are resulting in rise in the number of contract manufacturers in the region. Moreover, US hold the maximum intellectual property copyrights for majority of the newly developed medicines. The higher adoption rate of advanced healthcare services coupled with growing preferences for gene and cell therapies among the population is a major factor that propelled the demand for the plasmid DNA manufacturing market in North America. The continuous research and development activities towards the development of new biopharma medicines are expected to foster market growth in the forthcoming years. Along with the growth of the contract manufacturers, North America is also hub for the numerous contract research organizations that facilitates development of new medicines.
Asia Pacific is expected to witness highest growth rate throughout the forecast period owing to the growing manufacturing of plasmid DNA in the region. The world’s largest contract manufacturing company, GenScript started its operation in China by setting up a plasmid and virus facility in December 2019. This is a major development in the Asia Pacific plasmid DNA manufacturing market. Furthermore, the presence of Biocon in India and Samsung Biologics in South Korea are witnessing spike in their sales in the past few years. These factors are expected to boost the plasmid DNA manufacturing market in the region.
Key Players:
This report also provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the plasmid DNA manufacturing market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.
Some of the prominent players in the plasmid DNA manufacturing market include:
Segments Covered in the Report
By Product
By Application
By Disease
By Geography
Key Points Covered in plasmid DNA manufacturing market Study:
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Plasmid DNA Manufacturing Market, By Product
7.1. Plasmid DNA Manufacturing Market, by Product Type, 2021-2030
7.1.1. Viral Vectors
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Non-Viral
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Electroporation
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Lipid/Polymer
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Nanoparticles
7.1.6.1. Market Revenue and Forecast (2019-2030)
7.1.7. Others
7.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Plasmid DNA Manufacturing Market, By Application
8.1. Plasmid DNA Manufacturing Market, by Application, 2021-2030
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Plasmid DNA Manufacturing Market, By Disease
9.1. Plasmid DNA Manufacturing Market, by Disease, 2021-2030
9.1.1. Infectious Disease
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Genetic Disorder
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Disease (2019-2030)
Chapter 11. Company Profiles
11.1. VGXI, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Akron Biotech
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cobra Biologics & Pharmaceutical Services
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Aldevron
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Plasmidfactory GmbH
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Vigene Biosciences
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Luminous Biosciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Nature Technology Corporation
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Delphi Genetics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. JAFRAL Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1299
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://precedenceresearchnews.wordpress.com
Follow us on LinkedIn | Twitter | Facebook
Precedence Research recently published a report on “Drug of Abuse Testing Market (By Drug Type: Alcohol, Cocaine, Marijuana/Cannabis, LSD, Opioids,… Read More
Precedence Research recently published a report on “Digital Signage Market (By Component: Hardware, Software, Services; By Technology: LCD, LED, Projection;… Read More
Precedence Research recently published a report on “Beverage Packaging Market (By Material: Metal, Plastic, Glass, and Others; By Product: Bottles,… Read More
Precedence Research recently published a report on “Paper Cups Market (By type: Hot Paper Cups and Cold Paper Cups; By… Read More
Precedence Research recently published a report on “Fire Protection System Market (By Product: Fire Detection, Fire Suppression, Fire Response, Fire… Read More
This website uses cookies.